Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Chronic renal anemia~* Stable epoetin alfa or darbepoetin alfa therapy for past 2 months~* Hemodialysis therapy for ≥3 months~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months~* Poorly controlled hypertension requiring hospitalization or interruption of ESA treatment in previous 6 months~* Acute or chronic bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mircera in Renal Anemia (Type: EXPERIMENTAL): Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).

Based on this trial design, predict the completion outcome and termination type (if applicable).